Chemical compounds

TorHoerman Law Files First Paraquat Lawsuit in Vermilion County, IL

Retrieved on: 
Saturday, July 24, 2021
Chemical substances, Chemical compounds, Herbicides, Paraquat, Vermilion County, Henning High School, Vermilion, Chemistry

EDWARDSVILLE, Ill., July 24, 2021 /PRNewswire-PRWeb/ --TorHoerman Law attorney Chad Finley, a former resident of Vermilion County and graduate of Bismarck-Henning High School, on Wednesday filed the first paraquat lawsuit in Vermilion County, IL.

Key Points: 
  • EDWARDSVILLE, Ill., July 24, 2021 /PRNewswire-PRWeb/ --TorHoerman Law attorney Chad Finley, a former resident of Vermilion County and graduate of Bismarck-Henning High School, on Wednesday filed the first paraquat lawsuit in Vermilion County, IL.
  • The lawsuit, filed in the Fifth Judicial Circuit Court of Vermilion County (2021L000032), alleges paraquat exposure caused the plaintiff, a longtime resident of Vermilion County, to develop Parkinson's disease.
  • TorHoerman Law represents clients nationwide, with offices in Edwardsville, IL, Chicago, IL, and St. Louis, MO.
  • Chad began working as an attorney at TorHoerman Law in 2012 and has spent his entire career as an attorney at TorHoerman Law.

Exelixis to Release Second Quarter 2021 Financial Results on Thursday, August 5, 2021

Retrieved on: 
Thursday, July 22, 2021
Oncology, Health, Genetics, Clinical trials, Pharmaceutical, Biotechnology, Chemical compounds, Organic compounds, Orphan drugs, Drugs, Tyrosine kinase inhibitors, Cyclopropanes, Quinolines, Cabozantinib, Exelixis, Cobimetinib, NASDAQ, Daiichi Sankyo

Exelixis, Inc. (Nasdaq: EXEL) announced today that its second quarter 2021 financial results will be released on Thursday, August 5, 2021 after the markets close.

Key Points: 
  • Exelixis, Inc. (Nasdaq: EXEL) announced today that its second quarter 2021 financial results will be released on Thursday, August 5, 2021 after the markets close.
  • At 5:00 p.m. EDT / 2:00 p.m. PDT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update.
  • For more information about Exelixis, please visit www.exelixis.com , follow @ExelixisInc on Twitter or like Exelixis, Inc. on Facebook.
  • Exelixis, the Exelixis logo, CABOMETYX, COMETRIQ and COTELLIC are registered trademarks of Exelixis, Inc. MINNEBRO is a registered trademark of Daiichi Sankyo Company, Limited.

MarinOne Delivers Performance Across Advertising Channels

Retrieved on: 
Thursday, July 22, 2021
Companies, Marketing, Online advertising, Marin Software, Chemical compounds, LinkedIn, Marinone, Advertising, Apple Inc.

The MarinOne bidding algorithm can be used across channels, including the latest additions like Instacart, LinkedIn and Apple Search Ads.

Key Points: 
  • The MarinOne bidding algorithm can be used across channels, including the latest additions like Instacart, LinkedIn and Apple Search Ads.
  • "MarinOne enables brands to connect more effectively with customers," said Chris Lien, Marin's Chairman and CEO.
  • "The MarinOne solution has saved us time reporting on our LinkedIn campaigns and also provided a significant performance uplift leveraging its bidding technology."
  • Marin Software offers a unified SaaS advertising management platform for search, social, and eCommerce advertising.

Eiger BioPharmaceuticals to Host Conference Call for Second Quarter 2021 Financial Results and Business Update on Thursday, August 5

Retrieved on: 
Thursday, July 22, 2021
Branches of biology, Organic compounds, Chemical compounds, Senescence, Genodermatoses, Progeroid syndromes, Rare diseases, Laminopathy, Muscular dystrophy, Progeria, Lonafarnib, HGPS

PALO ALTO, Calif., July 22, 2021 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc.(Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that it will host a conference call onThursday, August 5, 2021at4:30 PM ET to discuss its financial results and provide a business update for the second quarter 2021.

Key Points: 
  • PALO ALTO, Calif., July 22, 2021 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc.(Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that it will host a conference call onThursday, August 5, 2021at4:30 PM ET to discuss its financial results and provide a business update for the second quarter 2021.
  • Eigeris a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases.
  • Lonafarnib is a first-in-class, oral prenylation inhibitor in a global Phase 3 trial.
  • Zokinvyfor the treatment of Hutchinson-Gilford Progeria Syndrome (HGPS or Progeria) and processing-deficient progeroid laminopathies is the Company's first FDA approved product.

Natural Grocers by Vitamin Cottage, Inc. Announces Third Quarter Fiscal Year 2021 Earnings Conference Call and Webcast

Retrieved on: 
Thursday, July 22, 2021
Health food stores, Organic compounds, Branches of biology, Chemical compounds, Vitamin Cottage Natural Grocers, Biomolecules, Vitamin C, Vitamin

LAKEWOOD, Colo., July 22, 2021 /PRNewswire/ -- Natural Grocers by Vitamin Cottage, Inc. (NYSE: NGVC) today announced that the Company will release its third quarter fiscal year 2021 financial results after the market close on Thursday, August 5, 2021.

Key Points: 
  • LAKEWOOD, Colo., July 22, 2021 /PRNewswire/ -- Natural Grocers by Vitamin Cottage, Inc. (NYSE: NGVC) today announced that the Company will release its third quarter fiscal year 2021 financial results after the market close on Thursday, August 5, 2021.
  • The conference ID is "Natural Grocers by Vitamin Cottage."
  • Natural Grocers by Vitamin Cottage, Inc. (NYSE: NGVC) is an expanding specialty retailer of natural and organic groceries, body care products and dietary supplements.
  • View original content to download multimedia: https://www.prnewswire.com/news-releases/natural-grocers-by-vitamin-cott...
    SOURCE Natural Grocers by Vitamin Cottage, Inc.

Orsini Specialty Pharmacy Announces Access To Tiopronin For The Treatment Of Severe Homozygous Cystinuria

Retrieved on: 
Thursday, July 22, 2021
Amino acids, Chemistry, Chemical compounds, Thiols, Non-proteinogenic amino acids, Tiopronin, Cystinuria, Solute carrier family, Cystine, Pharmacy, B(0,+)-type amino acid transporter 1, Penicillamine

ELK GROVE VILLAGE, Ill., July 22, 2021 /PRNewswire/ -- Orsini Specialty Pharmacy announced today that it is now dispensing tiopronin, the first available generic version, in the US, of THIOLA® (tiopronin). Tiopronin is a reducing and complexing thiol indicated, in combination with high fluid intake, alkali, and diet modification, for the prevention of cystine stone formation in adults and pediatric patients nine years of age and older with severe homozygous cystinuria, who are not responsive to these measures alone. For more information about tiopronin, please see the Full Prescribing Information.

Key Points: 
  • ELK GROVE VILLAGE, Ill., July 22, 2021 /PRNewswire/ -- Orsini Specialty Pharmacy announced today that it is now dispensing tiopronin, the first available generic version, in the US, of THIOLA (tiopronin).
  • Cystinuria is a rare, inherited disease characterized by the build-up of the amino acid cystine, a building block of most proteins, in the kidneys and bladder.
  • "High touch care coordination and collaboration drive our unique pharmacy care model, and we are honored to help provide access to tiopronin to patients with severe homozygous cystinuria."
  • Providing patients with comprehensive and compassionate care since 1987,Orsini is the leading, independent specialty pharmacy focused on rare diseases, gene therapies, and complex conditions.

Trial Launches to Evaluate GlycoMimetics’ Uproleselan Added to Cladribine Plus Low-Dose Cytarabine in AML Patients

Retrieved on: 
Thursday, July 22, 2021
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Acute myeloid leukemia, Orphan drugs, 7+3, Organochlorides, Organic compounds, Cladribine, Chemical compounds, Health, the Phase 1b/2 Clinical Trial, Uproleselan, GlycoMimetics, Inc., THE PHASE 1B/2 CLINICAL TRIAL, UPROLESELAN, GLYCOMIMETICS, INC.

GlycoMimetics, Inc. (Nasdaq: GLYC) announced today that clinicians have treated the first patient in a Phase 1b/2 study evaluating the companys lead drug candidate, uproleselan, added to cladribine plus low dose cytarabine (LDAC) in patients with treated secondary AML (ts-AML).

Key Points: 
  • GlycoMimetics, Inc. (Nasdaq: GLYC) announced today that clinicians have treated the first patient in a Phase 1b/2 study evaluating the companys lead drug candidate, uproleselan, added to cladribine plus low dose cytarabine (LDAC) in patients with treated secondary AML (ts-AML).
  • According to Eric Feldman, M.D., GlycoMimetics Chief Medical Officer, Patients with treated secondary AML have an extremely poor prognosis.
  • Our previous preclinical and clinical research supports the potential for these patients to benefit from the addition of uproleselan.
  • The Phase 1b/2 single-arm trial is enrolling patients 18 years or older, with a diagnosis of ts-AML who have not received therapy for their AML.

Strategy Analytics: Despite the Pandemic, GaAs Device Revenue Bounces Back in 2020

Retrieved on: 
Thursday, July 22, 2021
Technology, Hardware, Other Technology, Telecommunications, Chemistry, Physical sciences, Chemical compounds, Gallium arsenide, Optoelectronics, 5G, Gaas, RF Micro Devices

After 2019 saw the first decline in more than a decade, RF GaAs device revenue returned to growth in 2020.

Key Points: 
  • After 2019 saw the first decline in more than a decade, RF GaAs device revenue returned to growth in 2020.
  • The Strategy Analytics Advanced Semiconductor Applications (ASA) report RF GaAs Device Technology and Market Forecast: 2020 - 2025 identifies 5G devices and networks as the primary reason for this growth.
  • The report does go on to forecast that growth will resume, with RF GaAs device revenue approaching $9.5 billion by 2025.
  • Wider deployment of millimeter wave-capable 5G handsets and networks will be the main contributors to future RF GaAs device revenue growth.

Portnoy Law: Lawsuit Filed On Behalf of Johnson & Johnson Consumer, Inc. Investors

Retrieved on: 
Thursday, July 22, 2021
Chemical compounds, Chemical substances, Chemistry, Mutagens, Sunscreen, Aveeno, Johnson & Johnson, Benzene, Portnoy

LOS ANGELES, July 22, 2021 (GLOBE NEWSWIRE) -- ​The Portnoy Law Firm advises investors that a class action lawsuit has been filed on behalf of Johnson & Johnson Consumer, Inc. ("J&J" or "the Company") (NYSE : JNJ) consumers that purchased certain Aveeno and Neutrogena sunscreens that have dangerous and unacceptable levels of benzene, a known cancer-causing chemical.

Key Points: 
  • The Portnoy Law Firm advises investors that a class action lawsuit has been filed on behalf of Johnson & Johnson Consumer, Inc. ("J&J" or "the Company") (NYSE : JNJ) consumers that purchased certain Aveeno and Neutrogena sunscreens that have dangerous and unacceptable levels of benzene, a known cancer-causing chemical.
  • Investors are encouraged to contact attorney Lesley F. Portnoy , to determine eligibility to participate in this action, by phone 310-692-8883 or email , or click here to join the case.
  • "Johnson & Johnson continued to market these sunscreen products as safe and healthy for consumers after being alerted to dangerous levels of a known, cancer-causing chemical," said Keller Lenkner Partner Warren Postman.
  • The Portnoy Law Firm represents investors in pursuing claims arising from corporate wrongdoing.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against AcelRx, Ocugen, Tarena, and DraftKings and Encourages Investors to Contact the Firm

Retrieved on: 
Thursday, July 22, 2021
Drugs, Chemical compounds, Anilides, General anesthetics, Janssen Pharmaceutica, Piperidines, Analgesics, Sports betting, DraftKings, Sufentanil, Fentanyl, Security

The Company's lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain.

Key Points: 
  • The Company's lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain.
  • misbrand Dsuvia within the meaning of the Federal Food, Drug and Cosmetic Act (FD&C Act) and make its distribution violative.
  • For more information on the DraftKings class action go to: https://bespc.com/cases/DKNG
    About Bragar Eagel & Squire, P.C.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.